Scarica l'app Stockscreener
33.23
2.50%
0.81
Pre-mercato:
33.20
-0.03
-0.09%
Precedente Chiudi:
$32.42
Aprire:
$32.95
Volume 24 ore:
560.64K
Relative Volume:
0.69
Capitalizzazione di mercato:
$1.89B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
2.9252
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
-0.27%
1M Prestazione:
-6.18%
6M Prestazione:
-28.71%
1 anno Prestazione:
+52.92%
Intervallo 1D:
$32.40
$33.50
Intervallo di 1 settimana:
$31.39
$35.03
Portata 52W:
$21.18
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Confronta AGIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
33.23 | 1.89B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Increases By 8.0% - MarketBeat
Alpha Thalassemia Pipeline 2024: Clinical Trials Assessment, - openPR
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision (NASDAQ:AGIO) - Seeking Alpha
Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - Insider Monkey
Agios Pharmaceuticals announces key 2025 milestones, catalysts through 2026 - MSN
Agios Pharma Sets Milestones for Rare Disease Growth - TipRanks
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - The Manila Times
Agios' PYRUKYND Gets FDA Review for Thalassemia Treatment, Major Pipeline Progress for 2025 - StockTitan
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter
Agios' supplemental new drug application for its thalassemia treatment gets FDA nod - MSN
Agios Pharmaceuticals (AGIO-Q) QuotePress Release - The Globe and Mail
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5%Should You Sell? - MarketBeat
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND By Investing.com - Investing.com South Africa
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer – Company Announcement - Financial Times
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND - Investing.com India
FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia - The Manila Times
FDA Accepts Agios' PYRUKYND® Application for Thalassemia Treatment Expansion - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares - MarketBeat
Agios Pharmaceuticals executive sells shares worth $90,232 By Investing.com - Investing.com Canada
Agios Pharmaceuticals executive sells shares worth $90,232 - Investing.com
FDA liver injury warning label for Agios' Pyrukynd - The Pharma Letter
FDA approves label update for Agios's PYRUKYND By Investing.com - Investing.com Australia
Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
FDA approves label update for Agios’s PYRUKYND By Investing.com - Investing.com Nigeria
FDA approves label update for Agios's PYRUKYND - Investing.com India
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average PT from Brokerages - MarketBeat
JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - The Manila Times
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 12.0% in December - MarketBeat
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
Franklin Resources Inc. Buys Shares of 36,317 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Objective long/short (AGIO) Report - Stock Traders Daily
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 3.9%Should You Sell? - MarketBeat
Agios Pharmaceuticals' SWOT analysis: mitapivat potential drives stock outlook - Investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Agios gains EU orphan drug status for sickle cell treatment By Investing.com - Investing.com UK
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease - The Manila Times
Agios' Mitapivat Secures Coveted EU Orphan Drug Status for Sickle Cell Disease Treatment - StockTitan
Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 83 RS Rating - Investor's Business Daily
Agios Pharmaceuticals (NASDAQ:AGIO) Trading 5.2% HigherStill a Buy? - MarketBeat
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
State Street Corp Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Agios Pharmaceuticals Inc Azioni (AGIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Milanova Tsveta | Chief Commercial Officer |
Jan 06 '25 |
Sale |
32.18 |
2,804 |
90,233 |
18,906 |
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):